Summit Therapeutics, Inc. , shared on LinkedIn:
“Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen.
NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China.
Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type.
Full Press Release Here.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).“